PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBUCB announces U.S. FDA approvals for BIMZELX [®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis. More news. Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.
DNA RNA and Cells - Pipelinereview
WEBSep 13, 2024 · DNA RNA and Cells. 20 September 2024. Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP. 19 September 2024. 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day. 18 September 2024.
Exscientia and Sanofi Establish Strategic Research Collaboration to ...
WEBJan 7, 2022 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
First Wave BioPharma Announces Completion of Business
WEBMar 15, 2024 · Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease. James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement …
WEBMar 13, 2024 · Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations.
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 …
WEBMar 15, 2024 · NUV-1511 is the Company’s first drug-drug conjugate (DDC) to enter the clinic. NEW YORK, NY, USA I March 14, 2024 I Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company ...
Seneca Therapeutics, Inc. Presents Promising New Preclinical Data ...
WEBApr 11, 2022 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 ...
WEBApr 13, 2023 · Research conducted in collaboration with Boston Children’s Hospital and published in the peer-reviewed journal – Scientific Reports. BEDMINSTER, NJ, USA I April 13, 2023 IJubilant Therapeutics Inc., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced publication of ...
Pfizer Shares Co-Primary Endpoint Results from Post-Marketing …
WEBNEW YORK, NY, USA I January 27, 2021 I Pfizer Inc. (NYSE: PFE) announced today co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance (A3921133; NCT02092467). The primary objective of this study was to evaluate the safety of tofacitinib at two doses (5 mg twice daily and 10 mg twice daily) versus a TNF inhibitor (TNFi) in subjects with ...
Silence Therapeutics Announces Positive Topline 36-Week Data …
WEBMar 13, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.